Glucos Fresenius Kabi

Glucos Fresenius Kabi is a sterile intravenous solution for injection that contains glucose as the sole active ingredient. The product is supplied in an unspecified strength and is marketed in the European Union as a prescription‑only excipient used in parenteral nutrition. It provides a carbohydrate substrate for energy metabolism and serves as an osmotic agent for fluid replacement in clinical settings during hospital care and patient management.

Glucos Fresenius Kabi is indicated for several clinical situations where intravenous carbohydrate and fluid support are required.

- Management of hypoglycemia when oral glucose administration is not feasible. - Fluid replacement in patients with dehydration or electrolyte loss. - Component of parenteral nutrition regimens for patients unable to receive enteral feeding. - Support of energy needs during peri‑operative care. - Adjunct therapy for pediatric and neonatal patients requiring balanced carbohydrate provision.

Glucos Fresenius Kabi may be associated with a range of adverse reactions, most of which are related to its osmotic and metabolic properties.

Common: - Transient hyperglycemia, especially in patients with impaired glucose tolerance. - Local irritation or pain at the infusion site. - Electrolyte disturbances such as hyponatremia when large volumes are administered. - Nausea or mild gastrointestinal discomfort.

Serious: - Severe hyperglycemia leading to osmotic diuresis. - Fluid overload with risk of pulmonary edema in patients with compromised cardiac function. - Rare anaphylactic reactions to formulation components.

When using Glucos Fresenius Kabi, clinicians should consider several safety factors to minimize risk.

- Assess baseline blood glucose and monitor levels regularly during infusion. - Evaluate cardiac and renal function before administering large volumes. - Adjust infusion rate in patients at risk for fluid overload or electrolyte imbalance. - Use aseptic technique to prevent catheter‑related infections. - Avoid rapid bolus administration unless clinically indicated. - Document any adverse reactions and report serious events to pharmacovigilance authorities.

Glucos Fresenius Kabi can interact with other therapies that affect glucose metabolism or fluid balance.

Avoid: - Concurrent use of high‑dose insulin without appropriate glucose monitoring. - Co‑administration with other hyperosmolar solutions that may exacerbate fluid shifts.

Use with caution: - Diuretics, which may increase the risk of electrolyte disturbances. - Beta‑blockers, which can mask signs of hypoglycemia. - Corticosteroids, which may raise blood glucose levels. - Medications that affect renal function, such as ACE inhibitors or NSAIDs.